web analytics
-0.8 C
Munich
Saturday, November 26, 2022

The Exciting Rise of Canbiola Inc (CANB)

Canbiola Inc (CANB) has seen an explosive rise in recent weeks from pennies to highs of $0.135 before a small pullback to just below a dime. CANB has established itself as a volume leader in recent weeks and is now among to most popular and top traded stocks on the entire OTCBB.

CANB operates in the red hot cannabis market responsible for many of the hottest stocks on the OTCBB. The sector continues to be red hot as legal marijuana sales are expected to grow to more than $20 billion by 2022, from approximately $10 billion in 2018, according to Marijuana Business Daily.

Canbiola Inc (CANB) is a US Company embarking in the sale of a variety of Cannabidiol (CBD) based products. Canbiola is in the process of developing its own line of proprietary products as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. Cannabis is currently federally illegal and has legalized for medical purposes in some form in a limited number of states.

CANB also owns two technological solutions, Wrapmail (US Patent 8,572,275), which turns traditional email into a powerful marketing and branding tool, as well Prosperity Systems and the Bullseye platform of document management and compliance targeted at broker-dealers, public companies, and governmental agencies providing a flawless all-in-one solution for document management, retention and compliance. In May 2017 the Company changed their name from Wrapmail, Inc. to Canbiola Inc.

Canbiola, Inc. has already launched a number of products that are available on their corporate website such as Cannabidiol (CBD) based oils, creams, moisturizers, chews, vapes, isolate, gel caps, concentrate and water. Canbiola is committed to providing the highest quality and lowest cost hemp solutions with the highest purity standards in the industry.

CANB product offerings have been very popular so far and have resulted in fact growing revenues for the Company. According to their 10Q from August 17, CANB reported product sales of $148,248 for the 3 months ended June 30, compared to just $2,135 in 2017.

To Find out the inside Scoop on CANB Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

According to CANB corporate sales to Functional and Alternative medical practices has grown. The nationwide Roll-Out has begun and continues to grow dramatically due to a strong affiliation with very clear-cut distribution channels. CANB sees exponential growth to Doctors and Medical Practices nationwide selling Canbiola products.

Recently CANB acquired new equipment for use at the manufacturing facility located in Washington State where the company’s products are made. This allows the Company to roll out an entire new line of supplements and varieties of other products. This equipment includes a NJP-800 Automatic Capsule Filling Machine, a ZP-9 Rotary Tablet Press, a 2M Conveyor Belt Line, a Small Capsule Counter ZN-400, Additional Die Set for ZP-9 Tablet Press, YD-2 Tablet Tester, BY-400 Coating Machine, DPT-80 Blister Pack Machine, DCJ Liquid Sachet Packing Machine, DCF Powder Sachet Packing Machine and a SL-130 Automatic Labeling Machine.

Back in June CANB announced a Distribution and Licensing Agreement with Hudilab Inc., dba Endless Relief of Colorado. This new agreement will add to our continuing effort to grow the company’s revenue and product and service offerings. Endless Relief has developed and owns the Mobius Therapy Cannabidiol-Infused product line that delivers a specialized CBD formulation as transdermal medication delivered on its own or in conjunction with Transcutaneous Electrical Nerve Stimulation Therapy (TENS). The agreement calls for Canbiola to manufacture and to jointly market Endless Relief’s Mobius Therapy products.

“This new relationship expands our expertise in everything CBD, it will also broaden our product and service offerings,” stated Marco Alfonsi, Canbiola CEO.

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $22.7 million market valuation CANB has little debt and small but fast growing revenues. Canbiola is in the process of developing its own line of proprietary products that are already proving to be very popular as well as seeking synergistic value through acquisitions in the CBD and the medical cannabis industry. There is little wonder investors are flocking to CANB in droves in recent days, MJ stocks are on fire and this one is priced really, really cheap compared to the competition. We will be updating on CANB when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CANB.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.

Disclosure: we hold no position in CANB either long or short and we have not been compensated for this article.

 

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.